{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:49Z","timestamp":1790352109006,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01916-0","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:20:09Z","timestamp":1759490409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of SGLT2 inhibitors on angiography-derived coronary microcirculatory resistance and clinical outcomes in patients with coronary heart disease and type 2 diabetes: A cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Guangkuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"1916_CR1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics\u20142018 update: a report from the American heart association. Circulation. 2018;137:e67\u2013492.","journal-title":"Circulation"},{"key":"1916_CR2","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1016\/j.jacc.2018.09.042","volume":"72","author":"VR Taqueti","year":"2018","unstructured":"Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:2625\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1916_CR3","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.3390\/jcm9092880","volume":"9","author":"F Vancheri","year":"2020","unstructured":"Vancheri F, Longo G, Vancheri S, Henein M. Coronary microvascular dysfunction. J Clin Med. 2020;9:2880.","journal-title":"J Clin Med"},{"key":"1916_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jcin.2015.06.017","volume":"8","author":"JD Sara","year":"2015","unstructured":"Sara JD, Widmer RJ, Matsuzawa Y, Lennon RJ, Lerman LO, Lerman A. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015;8:1445\u201353.","journal-title":"JACC Cardiovasc Interv"},{"key":"1916_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jcin.2023.11.039","volume":"17","author":"Y Kanaji","year":"2024","unstructured":"Kanaji Y, Ahmad A, Sara JDS, Ozcan I, Akhiyat N, Prasad A, et al. Coronary vasomotor dysfunction is associated with cardiovascular events in patients with nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2024;17:474\u201387.","journal-title":"JACC Cardiovasc Interv"},{"key":"1916_CR6","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.jacc.2017.09.1104","volume":"70","author":"MT Osborne","year":"2017","unstructured":"Osborne MT, Bajaj NS, Taqueti VR, Gupta A, Bravo PE, Hainer J, et al. Coronary microvascular dysfunction identifies patients at high risk of adverse events across cardiometabolic diseases. J Am Coll Cardiol. 2017;70:2835\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"1916_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/XCE.0000000000000223","volume":"10","author":"A Sinha","year":"2020","unstructured":"Sinha A, Rahman H, Perera D. Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management. Cardiovasc Endocrinol Metab. 2020;10:22\u201330.","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"1916_CR8","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3390\/jcm12082964","volume":"12","author":"K Kopeva","year":"2023","unstructured":"Kopeva K, Grakova E, Maltseva A, Mochula A, Gusakova A, Smorgon A, et al. Coronary microvascular dysfunction: features and prognostic value. J Clin Med. 2023;12:2964.","journal-title":"J Clin Med"},{"key":"1916_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40256-017-0258-8","volume":"18","author":"Y Nozari","year":"2018","unstructured":"Nozari Y, Eshraghi A, Talasaz AH, Bahremand M, Salamzadeh J, Salarifar M, et al. Protection from reperfusion injury with intracoronary N-acetylcysteine in patients with STEMI undergoing primary percutaneous coronary intervention in a cardiac tertiary center. Am J Cardiovasc Drugs. 2018;18:213\u201321.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1916_CR10","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/MJT.0000000000000309","volume":"23","author":"A Eshraghi","year":"2016","unstructured":"Eshraghi A, Talasaz AH, Salamzadeh J, Salarifar M, Pourhosseini H, Nozari Y, et al. Evaluating the effect of intracoronary N-acetylcysteine on platelet activation markers after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Am J Ther. 2016;23:e44\u201351.","journal-title":"Am J Ther"},{"key":"1916_CR11","doi-asserted-by":"publisher","first-page":"115011","DOI":"10.1016\/j.biopha.2023.115011","volume":"164","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Li Z, Feng S, Lin S, Ge Z, et al. Coronary microvascular dysfunction and cardiovascular disease: pathogenesis, associations and treatment strategies. Biomed Pharmacother. 2023;164:115011.","journal-title":"Biomed Pharmacother"},{"key":"1916_CR12","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/biomedicines10092274","volume":"10","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, et al. Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options. Biomedicines. 2022;10:2274.","journal-title":"Biomedicines"},{"key":"1916_CR13","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2174\/1381612826666200213123029","volume":"26","author":"C Sardu","year":"2020","unstructured":"Sardu C, Paolisso G, Marfella R. Inflammatory related cardiovascular diseases: from molecular mechanisms to therapeutic targets. Curr Pharm Des. 2020;26:2565\u201373.","journal-title":"Curr Pharm Des"},{"key":"1916_CR14","doi-asserted-by":"crossref","unstructured":"Mehrpooya M, Vaseghi G, Eshraghi A, Eslami N. Delayed myocardial infarction associated with rituximab infusion: a case report and literature review. Am J Ther. 2016.","DOI":"10.1097\/MJT.0000000000000214"},{"key":"1916_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00125-015-3799-x","volume":"59","author":"BJ Von Scholten","year":"2016","unstructured":"Von Scholten BJ, Hasbak P, Christensen TE, Ghotbi AA, Kjaer A, Rossing P, et al. Cardiac 82Rb PET\/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia. 2016;59:371\u20138.","journal-title":"Diabetologia"},{"key":"1916_CR16","doi-asserted-by":"publisher","first-page":"e003995","DOI":"10.1161\/JAHA.116.003995","volume":"5","author":"M Sezer","year":"2016","unstructured":"Sezer M, Kocaaga M, Aslanger E, Atici A, Demirkiran A, Bugra Z, et al. Bimodal pattern of coronary microvascular involvement in diabetes mellitus. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2016;5:e003995.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"1916_CR17","doi-asserted-by":"publisher","first-page":"25757","DOI":"10.31083\/RCM25757","volume":"26","author":"FL Gurgoglione","year":"2025","unstructured":"Gurgoglione FL, Benatti G, Denegri A, Donelli D, Covani M, De Gregorio M, et al. Coronary microvascular dysfunction: insights on prognosis and future perspectives. Rev Cardiovasc Med. 2025;26:25757.","journal-title":"Rev Cardiovasc Med"},{"key":"1916_CR18","doi-asserted-by":"publisher","first-page":"H1167","DOI":"10.1152\/ajpheart.00566.2022","volume":"323","author":"G SenthilKumar","year":"2022","unstructured":"SenthilKumar G, Gutierrez-Huerta CA, Freed JK, Beyer AM, Fancher IS, LeBlanc AJ. New developments in translational microcirculatory research. Am J Physiol Heart Circ Physiol. 2022;323:H1167\u201375.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1916_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1916_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1916_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/0115748871323540241212060946","volume":"20","author":"A Eshraghi","year":"2025","unstructured":"Eshraghi A, Khalesi S, Amini K, Salleh FH, Sharifikia M, Hajmiri MS, et al. Empagliflozin ameliorates the oxidative stress profile in type 2 diabetic patients with heart failure and reduced ejection fraction: results of a randomized, double-blind, placebo-controlled study. Rev Recent Clin Trials. 2025;20:167\u201379.","journal-title":"Rev Recent Clin Trials"},{"key":"1916_CR22","doi-asserted-by":"publisher","first-page":"777083","DOI":"10.3389\/fphar.2021.777083","volume":"12","author":"C Sardu","year":"2021","unstructured":"Sardu C, Massetti M, Testa N, Martino LD, Castellano G, Turriziani F, et al. Effects of Sodium-Glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via miecc: inflammatory burden, and clinical outcomes at 5 years of Follow-Up. Front Pharmacol. 2021;12:777083.","journal-title":"Front Pharmacol"},{"key":"1916_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","volume":"22","author":"C Sardu","year":"2023","unstructured":"Sardu C, Trotta MC, Sasso FC, Sacra C, Carpinella G, Mauro C, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and maces in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22:80.","journal-title":"Cardiovasc Diabetol"},{"key":"1916_CR24","doi-asserted-by":"crossref","unstructured":"Sardu C, Massetti MM, Rambaldi P, Gatta G, Cappabianca S, Sasso FC et al. SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. Metabolism [Internet]. 2022 [cited 2025 Jul 19];137. Available from: https:\/\/www.metabolismjournal.com\/article\/S0026-0495(22)00121-4\/fulltext","DOI":"10.1016\/j.metabol.2022.155243"},{"key":"1916_CR25","doi-asserted-by":"publisher","first-page":"107759","DOI":"10.1016\/j.phrs.2025.107759","volume":"216","author":"C Sardu","year":"2025","unstructured":"Sardu C, Trotta MC, Marfella LV, D\u2019Amico G, La Marca C, Mauro C, et al. Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator. Pharmacol Res. 2025;216:107759.","journal-title":"Pharmacol Res"},{"key":"1916_CR26","doi-asserted-by":"publisher","first-page":"107095","DOI":"10.1016\/j.vph.2022.107095","volume":"146","author":"C Bruckert","year":"2022","unstructured":"Bruckert C, Matsushita K, Mroueh A, Amissi S, Auger C, Houngue U, et al. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2. Vascul Pharmacol. 2022;146:107095.","journal-title":"Vascul Pharmacol"},{"key":"1916_CR27","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai C, Guo Z, Chang X, Li Z, Wu F, He J, et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 2022;52:102288.","journal-title":"Redox Biol"},{"key":"1916_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","volume":"459","author":"S Cooper","year":"2019","unstructured":"Cooper S, Teoh H, Campeau MA, Verma S, Leask RL. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Mol Cell Biochem. 2019;459:121\u201330.","journal-title":"Mol Cell Biochem"},{"key":"1916_CR29","doi-asserted-by":"publisher","first-page":"18384","DOI":"10.1038\/s41598-021-97787-2","volume":"11","author":"M Nakao","year":"2021","unstructured":"Nakao M, Shimizu I, Katsuumi G, Yoshida Y, Suda M, Hayashi Y, et al. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. Sci Rep. 2021;11:18384.","journal-title":"Sci Rep"},{"key":"1916_CR30","doi-asserted-by":"publisher","first-page":"12681","DOI":"10.1038\/s41598-022-16763-6","volume":"12","author":"M-A Campeau","year":"2022","unstructured":"Campeau M-A, Leask RL. Empagliflozin mitigates endothelial inflammation and attenuates Endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption. Sci Rep. 2022;12:12681.","journal-title":"Sci Rep"},{"key":"1916_CR31","doi-asserted-by":"publisher","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","volume":"875","author":"B Ganbaatar","year":"2020","unstructured":"Ganbaatar B, Fukuda D, Shinohara M, Yagi S, Kusunose K, Yamada H, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic Apolipoprotein E-deficient mice. Eur J Pharmacol. 2020;875:173040.","journal-title":"Eur J Pharmacol"},{"key":"1916_CR32","doi-asserted-by":"publisher","first-page":"104781","DOI":"10.1016\/j.phrs.2020.104781","volume":"157","author":"D Cappetta","year":"2020","unstructured":"Cappetta D, De Angelis A, Ciuffreda LP, Coppini R, Cozzolino A, Miccich\u00e8 A, et al. Amelioration of diastolic dysfunction by Dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res. 2020;157:104781.","journal-title":"Pharmacol Res"},{"key":"1916_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","volume":"109","author":"M El-Daly","year":"2018","unstructured":"El-Daly M, Pulakazhi Venu VK, Saifeddine M, Mihara K, Kang S, Fedak PWM, et al. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by Inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. Vascul Pharmacol. 2018;109:56\u201371.","journal-title":"Vascul Pharmacol"},{"key":"1916_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12933-022-01607-4","volume":"21","author":"L Leccisotti","year":"2022","unstructured":"Leccisotti L, Cinti F, Sorice GP, D\u2019Amario D, Lorusso M, Guzzardi MA, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173.","journal-title":"Cardiovasc Diabetol"},{"key":"1916_CR35","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s13300-021-01083-1","volume":"12","author":"GP Sorice","year":"2021","unstructured":"Sorice GP, Cinti F, Leccisotti L, D\u2019Amario D, Lorusso M, Guzzardi MA, et al. Effect of Dapagliflozin on myocardial insulin sensitivity and perfusion: rationale and design of the DAPAHEART trial. Diabetes Ther. 2021;12:2101\u201313.","journal-title":"Diabetes Ther"},{"key":"1916_CR36","doi-asserted-by":"publisher","first-page":"e020418","DOI":"10.1161\/JAHA.120.020418","volume":"10","author":"M J\u00fcrgens","year":"2021","unstructured":"J\u00fcrgens M, Schou M, Hasbak P, Kj\u00e6r A, Wolsk E, Zerahn B, et al. Effects of empagliflozin on myocardial flow reserve in patients with type 2 diabetes mellitus: the SIMPLE trial. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2021;10:e020418.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"1916_CR37","doi-asserted-by":"publisher","first-page":"e0263481","DOI":"10.1371\/journal.pone.0263481","volume":"17","author":"HE Suhrs","year":"2022","unstructured":"Suhrs HE, Nilsson M, Bov\u00e9 KB, Zander M, Prescott E. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study. PLoS ONE. 2022;17:e0263481.","journal-title":"PLoS ONE"},{"key":"1916_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/clc.23962","volume":"46","author":"AA Mohammed","year":"2022","unstructured":"Mohammed AA, Zhang H, Abdu FA, Liu L, Singh S, Lv X, et al. Effect of nonobstructive coronary stenosis on coronary microvascular dysfunction and long-term outcomes in patients with INOCA. Clin Cardiol. 2022;46:204\u201313.","journal-title":"Clin Cardiol"},{"key":"1916_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejim.2021.05.027","volume":"92","author":"FA Abdu","year":"2021","unstructured":"Abdu FA, Liu L, Mohammed A-Q, Yin G, Xu B, Zhang W, et al. Prognostic impact of coronary microvascular dysfunction in patients with myocardial infarction with non-obstructive coronary arteries. Eur J Intern Med. 2021;92:79\u201385.","journal-title":"Eur J Intern Med"},{"key":"1916_CR40","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10554-021-02254-8","volume":"37","author":"R Scarsini","year":"2021","unstructured":"Scarsini R, Shanmuganathan M, Kotronias RA, Terentes-Printzios D, Borlotti A, Langrish JP, et al. Angiography-derived index of microcirculatory resistance (IMRangio) as a novel pressure-wire-free tool to assess coronary microvascular dysfunction in acute coronary syndromes and stable coronary artery disease. Int J Cardiovasc Imaging. 2021;37:1801\u201313.","journal-title":"Int J Cardiovasc Imaging"},{"key":"1916_CR41","doi-asserted-by":"publisher","first-page":"e37022","DOI":"10.1097\/MD.0000000000037022","volume":"103","author":"Z Qiu","year":"2024","unstructured":"Qiu Z, Wang Y, Liu Y, Zhou Z, Wang Z. Diagnostic value of angiography-derived index of microcirculatory resistance (AMR) for coronary microcirculatory dysfunction (CMD) and its prognostic significance in patients with chronic coronary syndromes in the smoking population. Med (Baltim). 2024;103:e37022.","journal-title":"Med (Baltim)"},{"key":"1916_CR42","first-page":"1027","volume":"98","author":"H Mejia-Renteria","year":"2021","unstructured":"Mejia-Renteria H, Lee JM, Choi K, Lee S, Wang L, Kakuta T, et al. Coronary microcirculation assessment using functional angiography: development of a wire\u2010free method applicable to conventional coronary angiograms. Catheter Cardiovasc Interv. 2021;98:1027\u201337.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1916_CR43","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/jpm12111798","volume":"12","author":"Y Fan","year":"2022","unstructured":"Fan Y, Fezzi S, Sun P, Ding N, Li X, Hu X, et al. In vivo validation of a novel computational approach to assess microcirculatory resistance based on a single angiographic view. J Pers Med. 2022;12:1798.","journal-title":"J Pers Med"},{"issue":"Suppl 2","key":"1916_CR44","first-page":"1040","volume":"97","author":"S Tu","year":"2021","unstructured":"Tu S, Ding D, Chang Y, Li C, Wijns W, Xu B. Diagnostic accuracy of quantitative flow ratio for assessment of coronary stenosis significance from a single angiographic view: a novel method based on bifurcation fractal law. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2021;97(Suppl 2):1040\u20137.","journal-title":"Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv"},{"key":"1916_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","volume":"25","author":"JA Spertus","year":"1995","unstructured":"Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonnell M, et al. Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1916_CR46","unstructured":"SciELO brazil - qualidade. de vida em portadores de doen\u00e7a arterial coron\u00e1ria: compara\u00e7\u00e3o entre g\u00eaneros qualidade de vida em portadores de doen\u00e7a arterial coron\u00e1ria: compara\u00e7\u00e3o entre g\u00eaneros [Internet]. [cited 2025 Apr 8]. Available from: https:\/\/www.scielo.br\/j\/ramb\/a\/7RStvkDjXGrp9jKmG7mdC5F\/?lang=pt"},{"key":"1916_CR47","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamacardio.2020.7478","volume":"6","author":"M Thomas","year":"2021","unstructured":"Thomas M, Jones PG, Arnold SV, Spertus JA. State of the Art review: interpreting the Seattle angina questionnaire as an outcome in clinical trials and in clinical care. JAMA Cardiol. 2021;6:593\u20139.","journal-title":"JAMA Cardiol"},{"key":"1916_CR48","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/biomedicines9101356","volume":"9","author":"T Salvatore","year":"2021","unstructured":"Salvatore T, Caturano A, Galiero R, Di Martino A, Albanese G, Vetrano E, et al. Cardiovascular benefits from gliflozins: effects on endothelial function. Biomedicines. 2021;9:1356.","journal-title":"Biomedicines"},{"key":"1916_CR49","doi-asserted-by":"publisher","first-page":"1232583","DOI":"10.1155\/2018\/1232583","volume":"2018","author":"K Batzias","year":"2018","unstructured":"Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsa E, Stampouloglou PK, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: A systematic review and Meta-Analysis. J Diabetes Res. 2018;2018:1232583.","journal-title":"J Diabetes Res"},{"key":"1916_CR50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, Kr\u00f6ller-Sch\u00f6n S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u201385.","journal-title":"Redox Biol"},{"key":"1916_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1479164117733626","volume":"15","author":"T Gaspari","year":"2018","unstructured":"Gaspari T, Spizzo I, Liu H, Hu Y, Simpson RW, Widdop RE, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for Inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15:64\u201373.","journal-title":"Diab Vasc Dis Res"},{"key":"1916_CR52","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/ehjcvp\/pvad053","volume":"9","author":"K Dimitriadis","year":"2023","unstructured":"Dimitriadis K, Adamopoulou E, Pyrpyris N, Sakalidis A, Leontsinis I, Manta E, et al. The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond. Eur Heart J - Cardiovasc Pharmacother. 2023;9:741\u201357.","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"key":"1916_CR53","doi-asserted-by":"publisher","first-page":"1109946","DOI":"10.3389\/fcvm.2023.1109946","volume":"10","author":"J Liu","year":"2023","unstructured":"Liu J, Wang Y, Zhang J, Li X, Tan L, Huang H, et al. Dynamic evolution of left ventricular strain and microvascular perfusion assessed by speckle tracking echocardiography and myocardial contrast echocardiography in diabetic rats: effect of Dapagliflozin. Front Cardiovasc Med. 2023;10:1109946.","journal-title":"Front Cardiovasc Med"},{"key":"1916_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, G\u00f6pel SO, Gr\u00f6nros J, Behrendt M, Sotak M, Miliotis T, et al. SGLT2 Inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob\u2013\/\u2013 mice. Cardiovasc Diabetol. 2019;18:16.","journal-title":"Cardiovasc Diabetol"},{"key":"1916_CR55","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018;17:108.","journal-title":"Cardiovasc Diabetol"},{"key":"1916_CR56","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2337\/db20-0921","volume":"70","author":"KM Lauritsen","year":"2020","unstructured":"Lauritsen KM, Nielsen BRR, Tolbod LP, Johannsen M, Hansen J, Hansen TK, et al. SGLT2 Inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a randomized double-blind, placebo-controlled crossover trial. Diabetes. 2020;70:800\u20138.","journal-title":"Diabetes"},{"key":"1916_CR57","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, et al. Mechanistic insights of empagliflozin in nondiabetic patients with hfref: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9:578\u201389.","journal-title":"JACC Heart Fail"},{"key":"1916_CR58","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"1916_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000534287","volume":"149","author":"B Gao","year":"2023","unstructured":"Gao B, Wu G, Xie J, Ruan J, Xu P, Qian Y, et al. Quantitative flow ratio-derived index of microcirculatory resistance as a novel tool to identify microcirculatory function in patients with ischemia and no obstructive coronary artery disease. Cardiology. 2023;149:14.","journal-title":"Cardiology"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01916-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:05:18Z","timestamp":1759493118000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01916-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1916"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01916-0","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethics Committee of Tianjin Fourth Central Hospital (No SZXLL-2024-KY023) and was conducted by the principles outlined in the Declaration of Helsinki. However, because this was a retrospective study, patient informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"380"}}